HRW is committed to measuring, managing and reducing their GHG emissions with the overall aim of limiting climate change.
This document sets out the methodology that HRW used to calculate their carbon emissions for FY22/23, the company baseline.
Total scope 1 and 2 GHG emissions were 26 tCO2e (market-based method), and emissions from selected scope 3 categories were 72 tCO2e (fuel- and energy- related activities, business travel and employee commuting).
GHG emissions have been measured for all operations relating to Healthcare Research Worldwide Ltd, “HRW” including any subsidiaries or joint ventures.
Emissions for FY22/23 cover those from 1st April 2022 – 31st March 2023 inclusive.
GHG emissions for the company have been measured in accordance with the GHG Protocol Corporate Standard, with reporting boundaries defined by the operational consolidation (control) approach.
Scope 2 emissions have been measured using both the location-based and market-based method, with the latter being used for performance tracking (baselines and targets).
GHG emissions have been calculated using conversion factors for carbon dioxide (CO2), methane (CH4) and nitrous oxide (N2O). There are no known emissions of other greenhouse gases. The emissions factors used are the UK Government conversion factors for 2023.
Emissions reported cover scope 1 and 2 and selected scope 3 sources. A description of all emission sources and their calculation method is presented in Table 1.
Table: Emission sources and methodology
Reported emissions are estimated to cover >95% of scope 1 and 2 emission sources, and ~50% of scope 3 emission sources. Steps to expand the data collected and improve data collection methods will be taken over the coming years.
HRW’s total measured scope 1, 2 and 3 emissions for FY22/23 were 98.0 tCO2e (market-based method).
Table 2: HRW’s scope 1, 2 and 3 GHG emissions for FY22/23.
The GHG emissions for FY22/23 form the baseline against which reduction targets will be set. Should these change significantly due to merger, acquisition, change of calculation methodology or discovery of significant errors, the baseline will be retrospectively recalculated and externally published. The significance threshold for this is set as a cumulative impact (increase or decrease) of >=5%.
Steps to expand and enhance data collection methods are recommended as follows:
We use cookies to give you the best possible experience. We can also use it to analyze the behavior of users in order to continuously improve the website for you. Data Policy